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Context: Prospective cohort studies have identified an
association between cannabis use and later psychosis-
related outcomes, but concerns remain about unmea-
sured confounding variables. The use of sibling pair analy-
sis reduces the influence of unmeasured residual
confounding.
Objective: To explore the association between canna-
bis use and psychosis-related outcomes.
Design: A sibling pair analysis nested within a prospec-
tive birth cohort.
Setting: Births at a Brisbane, Australia, hospital.
Participants: Three thousand eight hundred one young
adults born between 1981 and 1984 as part of the Mater-
University Study of Pregnancy.
Main Outcome Measures: Cannabis use and 3 psy-
chosis-related outcomes (nonaffective psychosis, hallu-
cinations, and Peters et al Delusions Inventory score) were
assessed at the 21-year follow-up. Associations between
duration since first cannabis use and psychosis-related
outcomes were examined using logistic regression ad-
justed for sex, age, parental mental illness, and halluci-
nations at the 14-year follow-up. Within 228 sibling pairs,
the association between within-pair differences in dura-
tion since first cannabis use and Peters et al Delusions
Inventory score was examined with general linear mod-
eling. The potential impact of attrition was examined.
Results: Duration since first cannabis use was associ-
ated with all 3 psychosis-related outcomes. For those with
duration since first cannabis use of 6 or more years, there
was a significantly increased risk of (1) nonaffective psy-
chosis (adjusted odds ratio, 2.2; 95% confidence inter-
val, 1.1-4.5), (2) being in the highest quartile of Peters
et al Delusions Inventory score (adjusted odds ratio, 4.2;
95% confidence interval, 4.2-5.8), and (3) hallucina-
tions (adjusted odds ratio, 2.8; 95% confidence interval,
1.9-4.1). Within sibling pairs, duration since first can-
nabis use and higher scores on the Peters et al Delusions
Inventory remained significantly associated.
Conclusions: Early cannabis use is associated with psy-
chosis-related outcomes in young adults. The use of sib-
ling pairs reduces the likelihood that unmeasured con-
founding explains these findings. This study provides
further support for the hypothesis that early cannabis use
is a risk-modifying factor for psychosis-related out-
comes in young adults.
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P ROSPECTIVE COHORT STUDIEShave found that early-onsetcannabis use is associated withan increased risk of psychosis-related outcomes.1-7 Based on
these studies and a range of other lines of
evidence, reviewshavegenerallyconcluded
that cannabis use is a risk-modifying factor
for theseoutcomes(ie, cannabisuse iscaus-
allyrelatedtopsychosis-relatedoutcomes).8-13
However, there are lingering concerns that
the association may reflect methodological
biases and unmeasured residual confound-
ing.14,15 In a recent meta-analysis, Moore and
colleagues11 noted that after adjusting for
various methodological issues, there were
often substantial reductions in the effect size
between cannabis use and later psychosis-
related outcomes. Because the pooled effect
size reported by Moore and colleagues was
modest (adjusted odds ratio, 1.41; 95% con-
fidence interval [CI], 1.20-1.65), the role of
residual confounding cannot be dis-
counted. In light of the limitations of ob-
servational epidemiology,16 it is understand-
able that there is debate about the public
health implications of these findings.15,17
Despite the oft-repeated concerns about
the role of residual confounding, the re-
search community has yet to explore the
association between cannabis and psycho-
sis outcomes using sibling pair designs.
Twin and other sibling pair studies pro-
vide a quasi-experimental design that can
Author Affiliations are listed at
the end of this article.
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help address the issue of residual confounding. Sibling
pair designs capitalize on between-sibling differences while
reducing the influence of unmeasured confounding fac-
tors, since differences are less likely to be attributable to
shared genetic and environmental exposures. Twin stud-
ies have explored cannabis use as a “gateway” to other
illicit drug use,18 but, to our knowledge, no study has used
a sibling pair design to examine the association between
cannabis use and psychosis-related outcomes. If a sig-
nificant association between cannabis use and psychosis-
related outcomes was not detected in sibling pairs, it would
seriously weaken the argument that cannabis use was a
risk-modifying factor for psychosis-related outcomes. The
aims of this study were to explore the association be-
tween cannabis use and multiple psychosis-related out-
comes in a birth cohort and to further examine if these
associations persisted within nested sibling pairs.
METHODS
PARTICIPANTS
The Mater-University Study of Pregnancy, and its outcomes, is a
prospectivestudyof7223womenandtheirsingletonoffspringwho
receivedantenatal careatamajorpublichospital inBrisbane,Aus-
tralia,between1981and1984.Thecohortmembers(andtheirmoth-
ers) were followed up at 5, 14, and 21 years (eFigure 1, http:
//www.archgenpsychiatry.com). Of the original sample, follow-up
responses were obtained for 3801 children (53%) at the 21-year
follow-up. Full details of the Mater-University Study of Preg-
nancy study design, sampling strategy, attrition, and follow-up
sample characteristics are available elsewhere.19
MEASUREMENT OF
MAIN EXPOSURES
At the 21-year follow-up, cannabis use was retrospectively as-
sessed via a self-report questionnaire. Cohort members were
asked “In the last month, how often did you use cannabis, mari-
juana, pot, etc?” Options for response were have never used,
used every day, every few days, once or so, and not in the last
month. A second question sought the age at which use of can-
nabis began. Based on these variables, and the cohort mem-
bers’ age at interview, we derived a measure of duration since
first cannabis use. This variable was categorized into 4 levels,
with those who had never used cannabis in 1 group (the ref-
erence group) and those who had used cannabis divided into
3 approximately equal groups (3 years, 4 or 5 years,6 years).
Because members of this birth cohort were assessed within a
relatively narrow age range, longer duration since first canna-
bis use is equivalent to an earlier age at first cannabis use.
To explore the validity of this item, we examined the asso-
ciation between duration since first cannabis use (a retrospec-
tive measure) vs a prospective measure of alcohol and illicit
drug use that was assessed at the 14-year follow-up as part of
the widely used Youth Self-Report20 (“I use alcohol and drugs
for nonmedicinal purposes”).
MEASUREMENT OF OUTCOME VARIABLES
We examined 3 psychosis-related outcomes. At the 21-year fol-
low-up, 2575 of the 3801 cohort members were administered
the computerized lifetime version of the Composite Interna-
tional Diagnostic Interview (CIDI).21 Not all cohort members
received the CIDI, but this was because of insufficient funding
rather than any systematic bias (see later for analyses related
to missing values). For the current study, we defined “case-
ness” as having an International Statistical Classification of Dis-
eases, 10th Revision (ICD-10)22 diagnosis of nonaffective psy-
chosis based on meeting the criteria for the diagnoses of either
schizophrenia (ICD-10 code F20), persistent delusional disor-
der (ICD-10 code F22), or acute and transient psychotic dis-
orders (ICD-10 code F23). We also examined the 21-item ver-
sion of the Peters et al Delusions Inventory (PDI), an instrument
used to measure delusional-like experiences in clinical and com-
munity populations.23,24 Finally, we examined 2 specific CIDI
items designed to assess the presence of auditory and visual hal-
lucinations. Cohort members were grouped into those who en-
dorsed no hallucination items vs 1 or more.
MEASUREMENT OF
POTENTIAL CONFOUNDERS AND
OTHER EXPLANATORY FACTORS
It is feasible that early psychotic-like experiences could influ-
ence both subsequent cannabis use and psychosis-related out-
comes at the 21-year follow-up. At the 14-year follow-up, 2 items
from the Youth Self-Report20 were chosen for their face validity
as psychotic-like experiences: “I hear sounds or voices that other
people think aren’t there” and “I see things that other people think
aren’t there.” Based on this same cohort, we previously re-
ported that these items were associated with both an increased
risk of nonaffective psychosis25 and high scores on the PDI26 at
the 21-year follow-up. Subjects were dichotomized into those
who responded “never” vs “sometimes” or “often.”
Parental mental illness is a potential confounding factor be-
cause this could influence both the risk of cannabis use and psy-
chotic-related outcomes in the offspring.27-30 At the 5, 14, and 21-
year follow-ups, mothers of the cohort members were asked to
report on specific parental mental illnesses (maternal or pater-
nal history of schizophrenia, alcohol abuse/dependence, and de-
pression or anxiety disorders). Subjects were dichotomized into
parental history of mental disorder present or absent.
MAIN AND PLANNED
SENSITIVITY ANALYSES
We used maximum likelihood logistic regression to examine
the associations between duration since first cannabis use and
each of the 3 main outcomes variables in separate analyses (ie,
nonaffective psychosis, PDI total score, and the CIDI halluci-
nation items). In keeping with previous analyses,26 the total score
of the PDI was divided into quartiles. For model 1, the analy-
ses were adjusted for sex and age of the cohort members at the
21-year follow-up (age at testing varied slightly at each follow-
up). For model 2, we also included adjustments for 2 addi-
tional variables: (1) parental mental illness and (2) hallucina-
tions at age 14 years as assessed on the Youth Self-Report.
Several planned sensitivity analyses were undertaken. For
the assessment of the PDI total score and CIDI hallucination
items, we conducted the analyses again excluding cohort mem-
bers who (1) received a CIDI-derived diagnosis of nonaffec-
tive psychosis (to examine psychotic-like experiences in the co-
hort members without diagnostic-level psychotic disorders) or
(2) reported any cannabis use in the month prior to the 21-
year follow-up interview (to reduce the potential influence of
acute intoxication or withdrawal on the outcome measures).
Cannabis use has also been associated with later depression and
anxiety.11 Using the major CIDI-derived diagnoses of depres-
sion (ICD-10 codes F32, F33, and F34) and anxiety disorders
(ICD-10 codes F40, F41, and F43), we examined the associa-
tion between duration since first cannabis use and the psychosis-
(REPRINTED) ARCH GEN PSYCHIATRY/ VOL 67 (NO. 5), MAY 2010 WWW.ARCHGENPSYCHIATRY.COM
441
©2010 American Medical Association. All rights reserved.
Downloaded From: http://archpsyc.jamanetwork.com/ by a UQ Library User  on 09/13/2015
related outcomes in models that adjusted for the presence of
these disorders. To focus on issues related to reverse causality,
we also examined the association between endorsement of hal-
lucination items at age 14 years on the Youth Self-Report and
both frequency of cannabis use and duration since first can-
nabis use (assessed at the 21-year follow-up), excluding those
who used cannabis before age 15 years.
SIBLING PAIR ANALYSIS
While the Mater-University Study of Pregnancy cohort was re-
stricted to singleton offspring, during the period of recruit-
ment several hundred sibling pairs were recruited into the study
(there were no sibships with greater than 2 members included
in the cohort). We identified 228 sibling pairs who partici-
pated in the 21-year follow-up and who provided information
on the variables of interest (60 male sibling pairs, 65 female
sibling pairs, and 103 mixed-sex sibling pairs). The maximum
between-sibling age difference was 4 years, with 92% of the sib-
lings differing in age by 3 years or less. Eighty-three percent of
the mothers of the sibling pairs reported no change in part-
ners over the period of the birth of the 2 siblings.
Following methods outlined elsewhere,31,32 an index sibling
was randomly selected, and difference scores between the sib-
lings for (1) years since first cannabis use and (2) PDI total score
were generated (index sibling minus other sibling). For ex-
ample, within a sibling pair, if (1) the index sibling had 6 years
since first cannabis use and a PDI total score of 10 items while
(2) the other sibling had 2 years since first cannabis use and a
PDI total score of 3 items, then (3) the years since first cannabis
use difference score would be 4 years and the PDI difference score
would be 7 items. For each sibling pair, the association between
years since first cannabis use difference score (the predictor vari-
able) vs the PDI difference score (the outcome variable) was ex-
amined, when adjusted for differences in sibling age and sex. Sib-
ling pairs that included a cohort member with an ICD-10diagnosis
of nonaffective psychosis were excluded from the main analysis.
It couldbeargued that siblingsdiscordant forcannabisuse (ie,
one sibling who had never used cannabis and a sibling who had
usedcannabis for severalyears)maydiffer inarangeof factors that
could impact both the exposure variables (ie, propensity to use il-
licitdrugs)andsubsequentmentalhealth.Thus,weundertookan
additionalplannedsensitivityanalysiswherewerestricted thesib-
ling pairs to those who both used cannabis.This analysis allowed
an even greater focus on the critical nonshared exposure (ie, du-
rationsincefirstcannabisuse)andthepsychosis-relatedoutcomes.
POTENTIAL IMPACT
OF MISSING DATA AND ATTRITION
We explored the influence of attrition using 2 methods. First,
we used SAS Proc MI and MIanalzye (SAS Institute Inc, Cary,
North Carolina) to explore the data under the assumption that
data were missing randomly. For the multiple imputation, we
included the variables of interest used in the earlier-
mentioned models and also variables known to be associated
with attrition in this cohort (ie, birth weight and various ma-
ternal variables at first clinic visit related to age, education, mari-
tal status, mental health, and smoking).19 We used logistic re-
gression based on 20 imputed data sets. Finally, based on the
assumption that the data were missing in a nonrandom fash-
ion, we undertook a post hoc modeling exercise to explore the
robustness of the main findings under a set of assumptions that
would be potentially challenging to these findings.
Analyses were performed using SAS version 9.1 (SAS Insti-
tute Inc). Written informed consent was obtained from the mother
at all data collection phases and from the young adult at the 21-
year follow-up. Ethical approval for this study was obtained from
the University of Queensland Ethics Committee.
RESULTS
In total, 3801 subjects (1806 males) were included in the
analyses, with mean (SD) age of 20.1 (0.90) years (range,
18 to 23 years). Overall, 65 subjects received a diagno-
sis of nonaffective psychosis (ICD-10 code F20 schizo-
phrenia, n=53; ICD-10 code F22 persistent delusional
disorder, n=3; and ICD-10 code F23 acute and transient
psychotic disorders, n=9), while 233 endorsed at least
1 CIDI hallucination item. The total PDI score ranged
from zero to 21 endorsed items (mean [SD], 5.1 [3.6]
items; median, 4.0 items). The quartiles for the PDI total
score divided the subjects into (1) 2 or less, (2) 3 or 4,
(3) between 5 and 7, and (4) 8 and more items. The as-
sociation between a range of demographic and potential
confounding variables is shown in Table 1. In keeping
with previous analyses, sex, age at testing, parental men-
tal illness, and hallucinations at age 14 years were sig-
nificantly associated with some or all of the psychosis-
related outcomes.
Table 1. Psychosis-Related Outcomes at the 21-Year Follow-up by Demographic and Covariate Factors
Covariate No. (%)a
Unadjusted OR (95% CI)
Nonaffective
Psychosis
PDI Total Score
(Highest vs Lowest Quartile)
CIDI Hallucination
Item Endorsement
Sex
M 1806 (47.5) 1 [Reference] 1 [Reference] 1 [Reference]
F 1995 (52.5) 1.7 (1.0-2.8)b 1.4 (1.2-1.7)b 1.5 (1.1-2.0)b
Cohort member age at 21-y follow-up, y
18-20 2599 (68.8) 1 [Reference] 1 [Reference] 1 [Reference]
21-23 1178 (31.2) 2.9 (1.4-5.8)b 0.7 (0.6-0.8)b 0.9 (0.7-1.2)
Parental mental illnessc 1122 (29.5) 0.8 (0.5-1.5) 1.3 (1.1-1.6)b 1.2 (0.9-1.6)
Youth Self-Report age 14 y auditory or visual hallucinationsd 601 (15.8) 2.2 (1.3-3.9)b 2.6 (2.0-3.4)b 3.2 (2.4-4.3)b
Abbreviations: CI, confidence interval; CIDI, Composite International Diagnostic Interview; OR, odds ratio; PDI, Peters et al Delusions Inventory.
aTotals may vary because of missing values.
bSignificant finding.
cSchizophrenia, alcohol abuse/dependence, depression, or anxiety.
dSometimes or often.
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At the 14-year follow-up, 283 cohort members (7.9%)
reported using alcohol or illicit drugs. At the 21-year fol-
low-up, 17.7% reported using cannabis for 3 or fewer
years, 16.2% for 4 to 5 years, and 14.3% used for 6 or
more years. Among those who had ever used, 52.6% had
not used in the previous month, 11.0% reported daily use,
13.8% reported use “every few days,” and 22.6% re-
ported use “once or so per month.” With respect to the
validity of the main exposure measure, there was a sig-
nificant and strong relationship between the prospec-
tive assessment of alcohol or illicit drug use at the 14-
year follow-up and longer duration since first cannabis
use at the 21-year follow-up (Wald test=231; df=3;
P .001). Those who reported alcohol or illicit drug use
at the 14-year follow-up were 15 times more likely to sub-
sequently report 6 years’ or more duration since first can-
nabis use (odds ratio, 14.7; 95% CI, 10.2-21.2).
Tables 2,3, and4 show the association between du-
ration since first cannabis use and the 3 psychosis-
related outcome measures. Only those with the longest
duration since first cannabis use were at significantly in-
creased risk of nonaffective psychosis: those with 6 or
more years duration since first cannabis use (ie, use since
around 15 years of age) were twice as likely to receive a
diagnosis of nonaffective psychosis.
In Table 3, only the highest vs lowest PDI total score
quartile odds ratios are shown. Compared with those who
did not use cannabis, cannabis users were significantly
more likely to be in the highest quartile of the PDI scores.
Those with a duration since first cannabis use of 6 or more
years were 4 times more likely to be in the top PDI score
quartile and twice as likely to endorse CIDI hallucina-
tion items (Table 4). There were significant linear trends
between the exposure variable and all 3 psychosis-
related measures: the longer the duration since first can-
nabis use, the higher the risk of the adverse outcomes.
For the PDI score and hallucination outcomes, we con-
ducted a sensitivity analysis excluding individuals with non-
affective psychosis and those who had used cannabis in the
month prior to the 21-year follow-up (eTable 1). The as-
sociation between years since first cannabis use and PDI
total score remained significant for those who had 4 years
or more since first cannabis use. With respect to CIDI hal-
lucination items, only those who had 4 or 5 years since first
cannabis use had a significantly increased risk of report-
ing hallucinations at age 21 years. When we made addi-
tional adjustments to the model to include the presence of
a depressive or anxiety disorder (eTable 2), the point es-
timates for all 3 analyses dropped slightly and the CIs be-
came more imprecise, suggesting that these factors influ-
enced the associations of interest. Only the analyses related
to years since first cannabis use and (1) PDI total scores
and (2) hallucinations remained statistically significant.
With respect to the potential for reverse causality, we
found that hallucinations at the 14-year follow-up were
significantly associated with longer duration since first
cannabis use by the 21-year follow-up (Table 5). Fur-
thermore, compared with those who did not report hal-
lucinations, those with hallucinations at the 14-year fol-
low-up were twice as likely to be using cannabis on a daily
basis at the 21-year follow-up (model 1, adjusted odds
ratio, 2.1; 95% CI, 1.4-2.9).
Within the sibling pair sample, there were 10 pairs who
were discordant for nonaffective psychosis (there were
no pairs concordant for nonaffective psychosis at the 21-
year follow-up). For the discordant sibling pairs, we cal-
culated the difference in years since first cannabis use for
the affected minus the nonaffected sibling. The median
difference was 1.5 years (mean [SD], 0.4 [3.3] years, range,
−6 to 4 years). However, within this small sample, there
was no significant difference in years since first canna-
bis use between the affected vs nonaffected siblings when
adjusted for age and sex (F1,5=0.60; P=.49). Concern-
ing the main analysis, within the nonaffected sibling pairs
(sib pairs=218), there was a significant association be-
Table 2. Association Between Duration Since First Cannabis Use and Nonaffective Psychosis at the 21-Year Follow-up
Duration Since
First Cannabis Use, y
Nonaffective Psychosis, No. (%)a Adjusted Odds Ratio (95% Confidence Interval)
Absent Present Model 1b Model 2c
Never 1246 (51.3) 26 (40.0) 1 [Reference] 1 [Reference]
3 482 (19.8) 15 (23.1) 1.5 (0.6-1.1) 1.5 (0.8-2.9)
4-5 399 (16.4) 12 (18.5) 1.6 (0.8-3.2) 1.6 (0.8-3.2)
6 310 (12.72) 12 (18.5) 2.2 (1.1-4.6)d 2.1 (1.002-4.3)d
aTotals may vary because of missing values.
bAdjusted for sex and age at testing. Test of linear trend: Wald 21=6.8; P=.009.
cAdjusted for sex, age at testing, hallucinations at age 14 years, and parental mental illness. Test of linear trend: Wald 21=5.8; P=.02.
dSignificant finding.
Table 3. Association Between Duration Since First Cannabis
Use and PDI Total Score Quartiles
Duration Since
First Cannabis
Use, y
PDI Total Score
(Lowest vs Highest Quartile), OR (95% CI)
Model 1a Model 2b
Never 1 [Reference] 1 [Reference]
3 1.6 (1.2-2.0)c 1.6 (1.2-2.1)c
4-5 2.5 (1.9-3.4)c 2.5 (1.9-3.3)c
6 4.3 (3.2-5.8)c 4.0 (3.0-5.5)c
Abbreviations: CI, confidence interval; OR, odds ratio; PDI, Peters et al
Delusions Inventory.
aAdjusted for sex and age at testing. Test of linear trend: Wald 23=155.6;
P=.001.
bAdjusted for sex, age at testing, hallucinations at age 14 years, and
parental mental illness. Test of linear trend: Wald 23=143.3; P .001.
cSignificant finding.
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tween years since first cannabis use and PDI total differ-
ence scores when adjusted for differences in age and sex
(F1,213=18.5;P .001). Compared with their sibling, those
with more years since first cannabis use were more likely
to have higher PDI total scores. The model (which ex-
plained 19% of the variance) found that for every addi-
tional year since first exposure to cannabis, the sibling
with the earlier age at first use had scored approxi-
mately 1 PDI item higher compared with their sibling (per
annum increase in PDI total score=0.8; 95% CI, 0.7-
0.9). The Figure shows a scatterplot with each point rep-
resenting 1 sibling pair. When sibling pairs were re-
stricted to those where both siblings had used cannabis
(100 sibling pairs), the significant relationship between
years of cannabis use and PDI scores persisted (F1,95=6.4;
P=.01) (eFigure 2).
The association between years since first cannabis use
and PDI total score was reexamined using imputed miss-
ing data (eTable 3). The significant findings persisted and
the point estimates and CIs remained essentially un-
changed. Finally, we modeled a conservative missing data
scenario where we assumed that (1) all subjects with miss-
ing data on years since first cannabis use were users and
randomly allocated them between 1 to 8 years’ duration
since first cannabis use and (2) those with missing val-
ues were more likely to have lower PDI total scores (to
challenge our main empirical finding) and randomly al-
located these subjects to the lower 2 PDI score quar-
tiles. The resulting effect sizes for model 2 fell sharply,
but compared with those who never used cannabis, the
association between 6 or more years’ duration since first
cannabis use and higher PDI total scores remained sta-
tistically significant.
COMMENT
Longer duration since first cannabis use was associated
with multiple psychosis-related outcomes in young adults.
Furthermore, we report for the first time, to our knowl-
edge, that this association persisted when examined in
sibling pairs, thus reducing the likelihood that the asso-
ciation was due to unmeasured shared genetic and/or en-
vironmental influences. There was a “dose-response” re-
lationship between the variables of interest: the longer
the duration since first cannabis use, the higher the risk
of psychosis-related outcomes. The key findings were ro-
bust in the face of various planned sensitivity analyses
and conservative tests related to attrition.
Compared with those who had never used cannabis,
young adults who had 6 or more years since first use of
cannabis (ie, who commenced use when around 15 years
or younger) were twice as likely to develop a nonaffective
psychosis and were 4 times as likely to have high scores
on the PDI. Further analyses demonstrated that these find-
ings were not due to a small group of individuals with psy-
chotic disorders nor to individuals who were acutely in-
toxicated with cannabis when completing the PDI.
Table 4. Association Between Duration Since First Cannabis Use and the Presence of Hallucinations at the 21-Year Follow-up
Duration Since
First Cannabis
Use, y
Any CIDI Hallucination Item, No. (%)a OR (95% CI)
Absent Present Model 1b Model 2c
Never 1182 (52.1) 90 (38.6) 1 [Reference] 1 [Reference]
3 449 (19.8) 48 (20.6) 1.5 (1.0-2.2) 1.4 (1.0-2.1)
4-5 370 (16.3) 41 (17.6) 1.5 (1.0-2.5) 1.5 (1.0-2.2)
6 268 (11.8) 54 (23.2) 2.8 (1.9-4.1)d 2.5 (1.7-3.7)d
Abbreviations: CI, confidence interval; CIDI, Composite International Diagnostic Interview; OR, odds ratio.
aTotals may vary because of missing values.
bAdjusted for sex and age at testing. Test of linear trend: Wald 21=28.5; P .001.
cAdjusted for sex, age at testing, hallucinations at age 14 years, and parental mental illness. Test of linear trend: Wald 21=12.7; P .001.
dSignificant finding.
Table 5. Association Between Hallucinations at 14-Year Follow-up and Duration Since First Cannabis Use
Assessed at 21-Year Follow-upa
Duration Since First Cannabis Use, No. (%)b
Never
Years
3 4-5 6
Any hallucination item at age 14 y, Youth Self-Report
Absent 1650 (52.7) 568 (18.1) 509 (16.3) 404 (12.9)
Present 277 (47.0) 91 (15.5) 95 (16.1) 126 (21.4)
Model 1c
Odds ratio (95% confidence interval) 1 [Reference] 1.0 (0.8-1.3) 1.1 (0.9-1.5) 1.9 (1.5-2.5)d
aExcluding those who used cannabis prior to age 15 years.
bTotals may vary because of missing values.
cAdjusted for sex and age at testing. Test of linear trend: Wald 23=29.8; P .001.
dSignificant finding.
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Sibling pair analysis provides the opportunity to con-
trol for a range of unmeasured potential confounding vari-
ables. We identified a small but significant positive as-
sociation between years since first cannabis use and scores
on the well-validated measures of delusional-like expe-
riences. Reassuringly, this association persisted when we
restricted the analysis to sibling pairs concordant for any
cannabis use. This more stringent analysis provided a
sharper focus on the critical nonshared exposure (ie, du-
ration since first cannabis use).
With respect to genetic background, the cohort mem-
bers within the sibling pairs shared the same mother, and
the majority (we assume) shared the same father. Because
of the age proximity of the siblings, we can also feel con-
fident that a range of family milieu and socioeconomic fac-
tors remained reasonably constant for the sibling pairs dur-
ing early childhood. Of course, a range of exposures would
still differ between the siblings (eg, the use of alcohol and
illicit substances), and we would expect these nonshared
exposures to become more prominent with age (eg, after
the cohort members left the family home).
The nature of the relationship between psychosis and
cannabis use is by no means simple. In keeping with pre-
vious findings,33 we confirmed that those with early-
onset hallucinations were more likely to have longer du-
ration since first cannabis use and to use cannabis more
frequently at the 21-year follow-up. This demonstrates
the complexity of the relationship: those individuals who
were vulnerable to psychosis (ie, those who had iso-
lated psychotic symptoms) were more likely to com-
mence cannabis use, which could then subsequently con-
tribute to an increased risk of conversion to a nonaffective
psychotic disorder. In addition, analyses that incorpo-
rated adjustments for depressive and anxiety-related
disorders led to a reduction in the strength of the asso-
ciation between cannabis use and psychosis-related out-
comes. This suggests that depression and/or anxiety dis-
orders may mediate or moderate the pathways between
cannabis use and psychosis-related outcomes. We plan
to further explore these issues in more detail in future
studies.
The main analyses relied on retrospective self-
assessment of duration since first cannabis use rather than
prospective self-report or objective drug screens.34 The main
predictor variable did not capture cumulative exposure to
cannabis. It is feasible that some cohort members may have
started cannabis use at a relatively young age and then
stopped. These subjects would have been allocated the same
duration since first cannabis use as those with early and
persistent usage. Those with psychosis-related outcomes
may have been less reliable in estimating the age at first using
cannabis, but there is no a priori reason to suspect that these
individuals would systematically underreport or overre-
port this variable. Furthermore, the strong association be-
tween alcohol and illicit drug use assessed at the 14-year
follow-up and longer duration since first cannabis use as-
sessed at the 21-year follow-up lends weight to the valid-
ity of the later variable.
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Figure. Sibling pair analysis. Correlation between within-pair difference in years of cannabis use vs difference in Peters et al Delusions Inventory (PDI) total score.
Each dot represents 1 sibling pair. Negative values indicate that the index sibling had lower values on the variable of interest compared with his or her sibling.
Vertical and horizontal blue lines represent zero (ie, no difference between the siblings). The solid line is the regression and the dotted lines show the 95%
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Our diagnosis of nonaffective psychosis at age 21 years
was not clinically validated, and our findings related to
nonaffective psychosis (which were the most fragile of
the 3 psychosis-related outcomes) should be inter-
preted cautiously. We hope to address the clinical valid-
ity of the CIDI-derived diagnoses in the cohort in future
follow-ups. Diagnostic instruments were not adminis-
tered at the 14-year follow-up; thus, we cannot confi-
dently exclude the possibility that some of the cohort
members may have developed psychosis as young ado-
lescents, which may have contributed to subsequent can-
nabis use. In addition, the assessment of psychotic-like
experiences at the 14-year follow-up were based on 2 hal-
lucination items only; no items related to delusional be-
liefs were available at this follow-up.
Like other birth cohort studies, attrition was evident by
the 21-year follow-up.25 While this was primarily due to
lack of resources to track all original cohort members rather
than refusal to participate, participants lost to follow-up
differed on a range of variables.19 However, results of re-
analyses based on imputed data were essentially un-
changed from the results based on actual data. We also un-
dertook post hoc modeling to test the robustness/fragility
of our main finding in the face of “challenging” scenarios
related to differential attrition. The direction and signifi-
cance of the key findings persisted in these analyses.
CONCLUSIONS
Our study has demonstrated an association between
duration since first cannabis use and psychosis-related
outcomes in young adults. The findings are consistent
with the 2 other birth cohort studies that have ad-
dressed this issue.6,7 Of particular interest, these find-
ings persisted within sibling pairs, thus reducing the
chance that these associations were influenced by un-
measured residual confounding. This study has also
highlighted the complexity of the relationship between
risk factors and mediating variables on psychosis-re-
lated outcomes, since those with early-onset psychotic
symptoms were also likely to report early cannabis use.
This study provides further support for the hypothesis
that early cannabis use is a risk-modifying factor for
psychosis-related outcomes in young adults. Apart
from the implications for policy makers and health
planners,15 we hope our findings will encourage further
clinical and animal model–based research to unravel
the mechanisms linking cannabis use and psychosis.35
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